Carbamazepine Extended-Release Tablets (II) Receive Drug Registration Certificate
July 31, 2026
Source: drugdu
54
ST Renfu(600079.SH) announced that its subsidiary, Yichang Renfu, recently received a Drug Registration Certificate for Carbamazepine Extended-Release Tablets (II) issued by the National Medical Products Administration. This drug is primarily used to treat epilepsy and trigeminal neuralgia.
https://finance.eastmoney.com/a/202607273822088834.html
By editor
Copyright©2026 Ddu. All rights reserved.
Read more on
- While Da Vinci Remains in “Remote Control” Mode, Cornerstone Robotics Has Evolved to “Autonomous Operation”—A Technological Leap for Domestic Surgical Robots July 31, 2026
- Levocarnitine Oral Solution Receives Drug Registration Certificate July 31, 2026
- Application for drug registration and marketing authorization of dapagliflozin tablets accepted July 31, 2026
- China Biopharmaceutical and Indonesia’s Tempo Scan establish a joint venture with China Biopharmaceutical holding a 51% stake to expand the Southeast Asian pharmaceutical market July 31, 2026
- Subsidiary’s application for clinical trial registration of GenSci144 tablets for domestic production approved July 31, 2026
your submission has already been received.
OK
Subscribe
Please enter a valid Email address！
Submit
The most relevant industry news & insight will be sent to you every two weeks.
